What Every Cannabis Operator, Bank, and Entrepreneur Must Understand About Rescheduling Before It Happens
We have all watched this moment build for years. The December 2025 executive order directing movement on cannabis rescheduling felt, to many of us, like the signal we had been waiting for. But between legal practice, business operations, and cannabis banking, we have learned the same lesson repeatedly: signals are not outcomes. The space between an executive order and an effective federal rule is exactly where the most consequential mistakes get made.
What we want to address directly is the gap between what the executive order promises and what it actually delivers. That gap is where operators are making decisions right now, and where the greatest exposure lives. Rescheduling is probable. It is not done. And the path between here and there runs through administrative hearings, proposed rulemaking, and litigation that is already being organized.
An Executive Order Begins a Process. It Does Not Complete One.
From a legal standpoint, the December 2025 executive order initiated the administrative hearing process for moving cannabis from Schedule I to Schedule III under the Controlled Substances Act. That hearing is still pending. No final rulemaking has been issued. Cannabis remains federally illegal today, exactly as it was before the order was signed.
We are already seeing operators and institutions treat this order as resolved policy, and that is a serious misjudgment. Post-hearing litigation is widely anticipated. The most realistic timeline for an effective rule is 2027 at the earliest. Build your compliance architecture, your tax structure, and your banking relationships around the legal environment as it exists. Treat rescheduling as upside, not foundation.
“The executive order initiates a process. Until that process concludes and a final rule is in place, every operator is still in a federally illegal space, and every business decision needs to reflect that reality.”
Rescheduling and Descheduling Are Not the Same Thing.
One distinction every operator must hold clearly is the difference between rescheduling and descheduling. Rescheduling moves cannabis within the Controlled Substances Act. Descheduling removes it entirely. Many in the cannabis community would strongly prefer descheduling, and that preference is well-founded. But what is on the table is rescheduling, and that carries specific legal consequences that operators need to understand now, not after a rule is finalized.
Under a Schedule III framework, operators who obtain DEA registration and comply with FDA oversight would operate within federal law, gaining access to interstate commerce and pharmaceutical-level legitimacy. Those who do not pursue DEA registration, the majority of adult-use and recreational businesses, would remain federally illegal despite holding valid state licenses. For manufacturers in states like New York, where Good Manufacturing Practice certification is already required, the pathway to DEA licensing may be closer than many realize.
Section 280E: The Most Consequential Financial Change With Looming Uncertainty.
Section 280E of the Internal Revenue Code prohibits ordinary business deductions for any entity trafficking in Schedule I or Schedule II substances. A move to Schedule III would, on its face, remove cannabis businesses from that prohibition. The financial impact would be significant, and we have watched operators absorb this burden for years. The prospect of relief is real.
What is also real is the legislative risk. Proposed legislation has already emerged that would keep 280E-style restrictions in place even after rescheduling, requiring separate congressional action to deliver the relief many founders are already projecting. Structure your chart of accounts to preserve optionality. Run parallel planning scenarios under the current regime and assuming relief. Do not commit to a single financial projection until congressional action confirms the outcome.
“Excitement about rescheduling is valid. But structuring your business around it before it is final is a risk most operators and entrepreneurs cannot afford to take. Build for where the law is, and design for where it may go.”
For Banks, the Compliance Burden Has Not Moved.
Rescheduling will not change the compliance obligations that govern cannabis banking. The 2014 FinCEN guidance remains in force regardless of scheduling status. The enhanced onboarding, the ongoing due diligence, the Suspicious Activity Report filings required even in the absence of suspicious activity, the Currency Transaction Reports that multiply rapidly in cash-intensive operations: none of that changes with a scheduling decision.
Institutions entering or expanding in the cannabis banking space should structure their programs around these obligations as standing requirements, not temporary constraints pending rescheduling. What may change over time is institutional appetite, particularly for operators who elect DEA registration and operate within a federal framework. But that is a downstream development, contingent on rulemaking that has not yet begun.
“I built a cannabis banking program from the ground up. The one thing every institution entering this space must understand is that the compliance infrastructure is permanent. Rescheduling does not reduce the filing stack. Plan for that from day one.”
Hemp Is Now the More Urgent Concern.
If rescheduling has generated optimism in parts of the cannabis industry, the appropriations bill provision inserted in November 2025 has done the opposite for hemp. That provision effectively recriminalized significant portions of the infused hemp market, with a one-year grace period. Hemp was the sector many considered safe, protected by the Farm Bill and attractive to banks unwilling to touch cannabis. That stability has been disrupted.
The ripple effects are already being felt across operators, lenders, patients, and supply chains. Hemp businesses and their banking partners should treat this as requiring immediate legal review of product classifications, contract structures, and banking relationships. Waiting for legislative resolution is not a strategy in an environment this fluid.
How to Position Now, Before the Rules Are Final.
For entrepreneurs and operators asking where to focus while rescheduling remains unresolved, our answer is consistent: build positions that are resilient to the ambiguity rather than dependent on its resolution. Ancillary businesses, those not directly touching the cannabis plant, offer lower capital requirements, fewer licensing hurdles, and meaningful insulation from regulatory shifts. Demand for technology, compliance consulting, legal services, and accounting persists regardless of how the federal framework evolves.
For those entering a specific state recreational market, the foundational work is research: understand the licensing framework, assess the existing medical market to gauge total addressable market, build the business model before committing to a license type. Skills developed in hemp cultivation, processing, and GMP practices transfer directly to cannabis operations. The knowledge built on one side of that legal line is fully applicable on the other.
The Bottom Line
We are not pessimistic about rescheduling. We believe it will happen. The political incentives are aligned, the administrative process has been initiated, and the current administration has expressed clear support. What we are realistic about is the timeline and the complexity. An effective rule is unlikely before 2027. Litigation will be contested. And the gap between rescheduling and the full legal clarity this industry ultimately needs remains wide.
The operators and institutions who will be best positioned when the rules finally change are the ones building durable programs today. Legal structures that work under 280E and can adapt if it disappears. Banking relationships built on full compliance, not regulatory optimism. Hemp businesses that have reviewed their exposure and acted. The market will not pause for clarity. Those who prepare for the complexity will be ready when it resolves.
Follow NCIA
Newsletter
Facebook
Twitter
LinkedIn
Instagram
–